⚠ AliExpress semaglutide — looking for input

This one has a reasonably settled answer, so here it is. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

NurseKim_ATL said:

The mechanism that matters here is not stomach emptying, it is central.

Agreeing with NurseKim_ATL, and the qualification matters more than the agreement. Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak. People who dose late are not losing a peak, they are letting the trough fall, and the appetite effect tracks the trough.

anna.melb_AU said:

The first four months were close to the trial curve and the last two have been flat, which is roughly what the STEP 1 figure predicts if you read the…

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Ask again with the specifics and you will get a better answer than this one.

Adding the clinical framing, because it changes how the question reads.

anna.melb_AU said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.